betaserc 24 mg tablete
mylan healtcare gmbh - betahistin - tableta - betahistin 15,6 mg / 1 tableta - betahistin
betaserc 24 mg orodisperzibilne tablete
bgp products b.v. - betahistin - orodisperzibilna tableta - betahistin 15,64 mg / 1 tableta - betahistin
betaserc 24 mg tablete
mylan healtcare gmbh - betahistin - tableta - betahistin 15,6 mg / 1 tableta - betahistin
betaserc 24 mg tablete
mylan healtcare gmbh - betahistin - tableta - betahistin 15,6 mg / 1 tableta - betahistin
rybrevant
janssen-cilag international n.v. - amivantamab - karcinom, pljučni pljuč - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
sixmo
l. molteni & c. dei fratelli alitti società di esercizio s.p.a. - buprenorfin hidroklorid - opioidne motnje - druga zdravila na živčnem sistemu - sixmo je primerna za nadomestno zdravljenje odvisnosti od opioidov v klinično stabilno odraslih bolnikih, ki ne zahtevajo več kot 8 mg/dan sublingual buprenorfin, v okviru medicinske, socialne in psihološke obravnave.
betaserc 16 mg
tableta - betahistin
kyleena 19,5 mg intrauterini dostavni sistem
bayer d.o.o. - levonorgestrel - intrauterini dostavni sistem - levonorgestrel 19,5 mg / 1 sistem - plastični maternični vložki z dodatkom progestogenov
levosert 20 mikrogramov/24 ur intrauterini dostavni sistem
gedeon richter plc. - levonorgestrel - intrauterini dostavni sistem - levonorgestrel 52 mg / 1 vložek - plastični maternični vložki z dodatkom progestogenov
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - druga zdravila na živčnem sistemu - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.